View Author
patient stent group lesion calci calci fied group noncalci fied group vessel study noncalci trial restenosi angiographic target artery spirit follow-up diameter month in-stent calci fied 6 months table analysis signi ficantly signi intervention calci fied lesions randomized difference result 10.1002/ ccd revascularization outcome spirit ii implantation angiography event characteristic 2 years infarction artery disease serruy 3 years ees implantation spirit ii trial culprit ficantly ef ficacy 1.0 value fication id-tlr treatment behalf calci fication catheterization 10.1002/ table iii 30 days noncalci fied lesions reference vessel diameter stenosi drug-eluting baseline ees group 1 year society target lesions xience procedure paclitaxel-eluting table ii everolimus-eluting stent vessel patients randomized spirit iii des patients population success target site revascularization
3 Most Recent Publications
|
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two-year angiographic and three-year clinical results from the SPIRIT II study
(Article)
Onuma, Y. Tanimoto, S. Thuesen, L. Dorange, C. Miquel, K. Veldhof, S. Serruys, P.W.J.C. Ruygrok, P.N. Neuzner, J. Piek, J.J. Seth, A. Schofer, J. Richardt, G. Wiemer, M. Carrié, D. |
2010-11-01
|
|
An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials
(Article)
Bartorelli, A. Serruys, P.W.J.C. Miquel, K. Yu, S. Pierson, W. Stone, G.W. |
2010-07-01
|
|
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
(Article)
Serruys, P.W.J.C. Ormiston, J.A. Thuesen, L. Zeiher, A.M. Bett, J.H. Suttorp, M.J. Glogar, H.D. Pitney, M. Wilkins, G.T. Whitbourn, R. Veldhof, S. Miquel, K. Sianos, G. Johnson, R. Coleman, L. Virmani, R. Feyter, P.J. de Sousa, J.E. Grube, E. Heijer, P. den Buszman, P. Schomig, A. Marco, J. Polonski, L. |
2004-10-06
|
